FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-02									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

1. Name and Address of Reporting Person* Klein Lawrence Otto						2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [CRSP]								eck all applic Directo	*		on(s) to Issi 10% Ow Other (s	/ner	
	SPR THER	APEUTICS, IN	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/10/2020								A below)			below)	-	
610 MAIN STREET					4. If	If Amendment, Date of Original Filed (Month/Day/Year)							6. Ir	6. Individual or Joint/Group Filing (Check Applicable					
(Street) CAMBRIDGE MA 02139												Line	Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)											Felson					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,		Code (Instr. 5)			Beneficia Owned F	es Form ally (D) of Following (I) (II		Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership						
								Code V		Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	ate, T	ransac Code (li				6. Date Exercisal Expiration Date (Month/Day/Year			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)		Date Exercisable	Ex Da	piration ite	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$44.67	03/10/2020			A		55,000		(1)	03/	/10/2030	Common Shares	55,000	\$0.00	55,000		D		
Restricted Stock	(2)	03/10/2020			A		13.750		(3)		(3)	Common	13 750	\$0.00	13.750		D		

Explanation of Responses:

- 1. This option was granted on March 10, 2020 with respect to 55,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020.
- 2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- 3. This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2021, (i 10, 2022, and (iii) one third of the shares vesting on March 10, 2023.

Remarks:

/s/ Michael Esposito, attorneyin-fact

03/12/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.